Abbott Laboratories

Equities

ABT

US0028241000

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 16:00:02 2024-05-10 EDT			5-day change	1st Jan Change
104.7 ^USD	+0.07%		-1.10%	-4.84%

05-09	Drugmaker Abbott India posts Q4 profit rise on higher sales	RE
05-08	Abbott Laboratories Insider Sold Shares Worth $2,428,119, According to a Recent SEC Filing	MT

Abbott Laboratories Announces Retirement of Greg W. Linder as Vice President and Controller, Effective from February 28, 2013

July 13, 2012 at 05:02 pm

Abbott Laboratories announced that Greg W. Linder, Vice President and Controller will retire from the company effective February 28, 2013. Robert E. Funck has been appointed Vice President and Controller, effective March 1, 2013.

Latest news about Abbott Laboratories

Drugmaker Abbott India posts Q4 profit rise on higher sales	05-09	RE
Abbott Laboratories Insider Sold Shares Worth $2,428,119, According to a Recent SEC Filing	05-08	MT
Abbott's Dissolving Stent Gets FDA Approval For Arteries Below the Knee	04-29	MT
Dexcom's profit beats estimates on strong glucose monitor demand	04-25	RE
Edwards Lifesciences first-quarter profit beats estimates on heart devices strength	04-25	RE
Daiwa Securities Trims Abbott Laboratories Price Target to $125 From $126	04-23	MT
Barclays Adjusts Abbott Laboratories' Price Target to $140 From $141, Maintains Overweight Rating	04-22	MT
UBS Raises Abbott Laboratories Price Target to $143 from $136, Buy Rating Kept	04-19	MT
Correction to Health Care Roundup Article	04-18	DJ
RBC Lowers Price Target on Abbott Laboratories to $125 From $128, Keeps Outperform Rating	04-18	MT
Raymond James Adjusts Abbott Laboratories' Price Target to $124 From $127, Keeps Outperform Rating	04-18	MT
Health Care Down After Abbott Earnings -- Health Care Roundup	04-17	DJ
Sector Update: Health Care Stocks Retreating Late Afternoon	04-17	MT
News Highlights : Top Company News of the Day - Wednesday at 3 PM ET	04-17	DJ
S&P 500, Nasdaq dip as interest rate concerns, earnings weigh	04-17	RE
Abbott Laboratories Raises Midpoint of 2024 Guidance After First-Quarter Beat	04-17	MT
Top Stories at Midday: U.S. Bancorp, Abbott, Citizens Financial, First Horizon, Prologis, ASML, Travelers Report Earnings; Tesla Asks Shareholders Vote on Musk's Compensation; Eli Lilly Sleep Apnea Drug Trials Hit Primary Endpoints	04-17	MT
News Highlights : Top Company News of the Day - Wednesday at 1 PM ET	04-17	DJ
News Highlights : Top Company News of the Day - Wednesday at 11 AM ET	04-17	DJ
Wall St slips as dour earnings, chip stocks weigh	04-17	RE
Sector Update: Health Care Stocks Advance Premarket Wednesday	04-17	MT
News Highlights : Top Company News of the Day - Wednesday at 9 AM ET	04-17	DJ
Transcript : Abbott Laboratories, Q1 2024 Earnings Call, Apr 17, 2024	04-17
Abbott: target ranges for 2024 tightened upwards	04-17	CF
Abbott Laboratories' Q1 Adjusted Earnings Down, Revenue Up; 2024 Outlook Narrowed	04-17	MT

Chart Abbott Laboratories

Duration

Period

More charts

Company Profile

Abbott Laboratories specializes in the research, development, manufacturing and marketing of pharmaceutical and medical products. Net sales break down by family of products as follows: - diagnostic systems and instruments (39.1%); - vascular devices (24.7%): endoprosthetic systems, dilation catheters, arterial closures, etc.; - nutrition products (12.1%): pediatric nutrition products, nutritional supplements, and dietetic products; - medicine (8.2%): anesthetics, antiviral products, antibiotics, inhibitors, anti-inflammatories, etc.; - other (15.9%). Net sales are distributed geographically as follows: the United States (38.5%), Germany (5.8%), China (5.6%), India (4.4%), Switzerland (4.1%), Japan (3.8%), Netherlands (2.7%) and others (35.1%).

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-07-17 - Q2 2024 Earnings Release (Projected)

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Abbott Laboratories

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

104.7 USD

Average target price

126.1 USD

Spread / Average Target

+20.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ABBOTT LABORATORIES	-4.84%	182B
MEDTRONIC PLC	+0.56%	110B
BECTON, DICKINSON AND COMPANY	-3.35%	68.11B
DEXCOM, INC.	+2.39%	50.53B
CENCORA, INC.	+9.36%	44.8B
HOYA CORPORATION	+2.70%	40.7B
METTLER-TOLEDO INTERNATIONAL, INC.	+24.51%	32.3B
WEST PHARMACEUTICAL SERVICES, INC.	+3.43%	26.53B
TERUMO CORPORATION	+13.67%	25.02B
ZIMMER BIOMET HOLDINGS, INC.	-0.32%	24.96B

Other Medical Equipment, Supplies & Distribution